Replies to post #3853 on Arch Therapeutics Inc (ARTH)

[bryan2464]

I guess when you get funding thru Maxim for a few million ... you'll end up losing about 45 million in market cap even after materially good release. Anyone check the math? Who's making the decisions?

[BonelessCat]

From clinicaltrials.gov website:

Arms Assigned Interventions

Experimental: AC5 Treatment on Wound
Treatment of skin lesion with topical hemostatic (AC5)

Device: Application of AC5 Hemostatic agent

Application of the hemostatic agent will be applied to the skin lesion directly as prescribed


Active Comparator: Standard Treatment of Wound
Treatment of skin lesion with water resistant dressing

Device: Standard application of water resistant dressing
Application of a water resistant dressing to the skin lesion as prescribed
https://clinicaltrials.gov/ct2/show/NCT02704104?term=AC5+arch&rank=1

The current standard of care is aluminum chloride topical dressing for both malignant and nonmalignant tumor removal (neoplasmic excision). Average time to hemostasis is about 80 seconds. A 41% reduction would be 47 seconds.

These are from online sources, so if anyone knows better or especially anyone with experience in this area, please feel free to correct or further detail the above.